Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease

Cheng-Chun Ji; Shota Takano

doi:10.5217/ir.2017.15.2.182

Articles

Page Path: HOME > Intest Res > Volume 15(2); 2017 > Article

Original Article Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease: Cheng-Chun Ji, Shota Takano; Intestinal Research 2017;15(2):182-186.
DOI: https://doi.org/10.5217/ir.2017.15.2.182
Published online: April 27, 2017

Coloproctology Center, Takano Hospital, Kumamoto, Japan.

Correspondence to Shota Takano, Coloproctology Center, Takano Hospital, 4-2-88 Obiyama, Chuo-ku, Kumamoto 862-0924, Japan. Tel: +81-96-384-1011, Fax: +81-96-385-2890, micg@takano-hospital.jp

• Received: August 10, 2016 • Revised: October 6, 2016 • Accepted: October 12, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

5,996 Views
76 Download
22 Web of Science
25 Crossref
24 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
Infliximab has proven to be effective in the treatment of perianal fistulas in Crohn's disease (CD) but the efficacy of adalimumab is still unclear. The aim of this study is to assess the clinical efficacy of adalimumab and compare the results with those for infliximab.
Methods
Forty-seven CD patients treated for perianal fistulas with infliximab from September 2005 to December 2010 (n=31), or with adalimumab from November 2010 to May 2012 (n=16), were enrolled in this retrospective study. The following patient characteristics were analyzed; intestinal lesion site, fistula classification, seton placement, index of inflammatory bowel disease, C-reactive protein level, follow-up period, and the cumulative rate of nonrecurrence or aggravation of fistula.
Results
There were no significant differences in the intestinal lesion site, fistula classification, inflammatory bowel disease index, C-reactive protein level, and the frequency of injection between the infliximab group and the adalimumab group. The cumulative rate of nonrecurrence or aggravation of fistula was 62.5% in the adalimumab group and 83.9% in the infliximab group at 24 months after treatment (P=0.09). The risk factors for recurrence or aggravation may be related to seton placement (P=0.02), gender (P=0.06), and fistula classification (P=0.07).
Conclusions
There was no significant difference in the clinical efficacy of adalimumab and infliximab in the treatment of perianal fistulas in CD. However, fistula classification may be an important risk factor for recurrence or aggravation. The preliminary findings in this study show that further research is warranted.
Keywords: Crohn disease; Perianal fistula; Adalimumab; Infliximab

INTRODUCTION

The incidence of CD is higher in Western industrialized countries. The prevalence of CD in children younger than 20 years of age is 43 (95% CI, 40–45) per 100,000 people and for adults it is 201 (95% CI, 197–204) per 100,000 people.1 However, a large-scale population-based study found that CD is becoming more common in Asia, especially in China (122/100,000) and Japan, and that the symptoms in patients with CD are often more severe in Asia than in the West.2 3 4

Penner and Crohn5 first reported that perianal fistulas were a complication of CD in 1938. Sometimes perianal fistula is the first recognizable symptom of CD. Perianal fistulas in CD may arise from inflamed or infected anal glands and/or penetration of fissures or ulcers in the rectum or anal canal. Some studies have shown that CD patients with perianal fistulas often require a combined surgical and medical approach because of frequent recurrence and abscess formation.6

Infliximab (IFX) and adalimumab (ADA) have proven to be effective in the treatment of perianal fistulas in CD,7 8 but it is not clear which is more effective. Therefore, the aim of this study was to determine the clinical efficacy of ADA compared with IFX in the treatment of perianal fistulas in CD, and to analyze the risk factors associated with recurrence or aggravation of the fistula tract.

METHODS

1. Patient Selection

All 47 consecutive CD patients treated for perianal fistulas with IFX from September 2005 to December 2010 (n=31) or with ADA from November 2010 to May 2012 (n=16) were enrolled in this study.

2. Study Design

The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) index, the CRP levels, and the number of recurrent or aggravated cases during the follow-up period were retrospectively analyzed. The IOIBD index consists of the following 10 factors: abdominal pain, diarrhea (>6 times per day), an anal lesion, a fistula, other complications, an abdominal tumor, weight loss, high fever, abdominal tenderness, and hemoglobin <10 g/dL. Each factor is scored as yes=1 point and no=0. All patients consented to receive either ADA or IFX treatment as part of a compassionate-use program. The patients were given details about each therapy and selected their own treatment. Clinical follow-up took place at 2, 6, and 8 weeks, and at 8-week intervals for 2 or more years after initial treatment.

3. Clinical Therapy Methods

The CD diagnosis was based on clinical symptoms, endoscopies, histopathological biopsies, CRP and other relevant blood examinations. The diagnosis of perianal fistula was based on the results of an MRI, endoanal ultrasound, and an examination under anesthesia by experienced colorectal surgeons. Fistulotomy was done for the SC fistula and a drainage seton was used for other fistulas. The indication for tumor necrosis factor-α (TNF-α) antibodies was based on the abdominal condition. When steroid hormones or immunomodulatory agents showed a loss of response, TNF-α antibodies were considered. IFX (5 mg/kg) induction was administered at week 0, 2, and 6 and maintenance therapy at 8-week intervals. ADA induction treatment was started at a dose of 160 mg and an additional 80 mg 2 weeks later. Maintenance therapy was 40 mg every 2 weeks.

4. Clinical Evaluation

The following definitions were taken from the IOIBD guidelines: recurrence is the reappearance of symptoms after healing, and aggravation is defined as discharge, swelling, or pain that becomes more serious without treatment. Complete healing is defined as no symptoms or drainage for a minimum of 2 weeks.

5. Statistical Analysis

Quantitative variables were analyzed using Student t-test. Categorical data are shown as the number and proportion of cases (%). The chi-square test was used to assess the categorical variables. Univariable and multivariable logistic regression were used to assess the risk factors for recurrence or aggravation. The OR for the outcomes (including 95% CI) was estimated for each variable in the model. Statistical analysis was performed by using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). A P-value less than 0.05 was considered statistically significant.

RESULTS

1. Patient Characteristics

1) The IFX Group

Twenty-seven of the 31 patients (87.1%) were male and four (12.9%) were female, with a mean age of 29.2±8.9 years and a mean disease duration of 7.2±6.8 years. According to the American Gastroenterological Association classification, 54.8% of the patients (17/31) had a simple anal fistula and 45.2% (14/31) had a complex anal fistula; 64.5% (20/31) required a seton. The follow-up period was 68.1±11.7 months.

2) The ADA Group

Fourteen of the 16 patients (87.5%) were male and two (12.5%) were female, with a mean CD onset age of 32.4±9.7 years and a mean disease duration of 8.9±6.5 years. The fistula classification were as follows: 56.3% of the patients (9/16) had a simple anal fistula and 43.8% (7/16) had a complex anal fistula; 68.8% (11/16) required a seton. The follow-up period was 36.1±3.9 month.

There were no differences in gender, disease duration, age of CD onset, intestinal location (large intestine and/or small intestine), fistula classification, seton placement, IOIBD score, CRP, and frequency of injection between the IFX and ADA groups (P>0.05) (Table 1).

2. Cumulative Rate of Nonrecurrence or Aggravation of Fistula

The cumulative rate of nonrecurrence or aggravation of fistula was 62.5% in the ADA group and 83.9% in the IFX group at 24 months after treatment (Fig. 1).

3. Univariate Analysis of the Risk Factors for Recurrence or Aggravation

The risk factors for recurrence or aggravation were significantly correlated with seton placement in this study (P<0.05). Moreover, the risk factors may be related to gender and fistula classification but no clear correlation was found (P<0.05). Age, intestinal location, disease duration, IOIBD score, CRP level, elemental diet, immunomodulator use, follow-up period, and IFX/ADA induction were not identified as risk factors for recurrence or aggravation (P<0.05) (Table 2).

4. Multivariate Analysis of the Risk Factors for Recurrence or Aggravation

The risk factors for recurrence or aggravation were correlated with seton placement (P<0.05). Moreover, the risk factors may be related to fistula classification but no clear correlation was found (P<0.05). There was no significant correlation between the risk factors for recurrence or aggravation and IFX/ADA induction (P<0.05) (Table 3).

DISCUSSION

TNF-α antibodies (IFX, ADA, and certolizumab) are effective for both induction and maintenance in moderate to severe CD in adults (including patients with a perianal fistula).9 IFX is a chimerical monoclonal antibody comprised of 75% human and 25% mouse sequences. However, the murine component is potentially antigenic for humans. Repeated infusion may cause the patient's immune system to produce antibodies against IFX that may reduce the efficacy of the drug, and may even cause anaphylactic shock.10 In order to lower the risk of negative immunogenic responses induced by chimeric antibodies, new studies attempted to replace the mouse-derived sequences to create fully human monoclonal antibodies. The result was the development of ADA, the first fully human antibody to be approved for clinical treatment. Some studies have found that ADA was more effective in short-term clinical response/remission, in long-term remission, and in obtaining complete fistula healing, compared with placebo. ADA has also proven to be effective in patients who no longer respond to or who develop intolerance to IFX.11

Perianal fistula in CD is usually difficult to treat because of the high rate of relapse after cessation of treatment. Although the introduction of IFX has increased the efficacy, the results are still disappointing, especially for complex fistulas. A British study showed that only 29% and 42% of the patients achieved complete or partial remission, respectively, when treatment combined a surgical procedure with IFX.12 Echarri et al.13 found that complete cessation of drainage occurred in 50% of the short-term cases, and that 87.5% were able to maintain this effect over time (follow-up period of 48 weeks). Sands et al.14 reported abscess development in patients with fistulizing CD was not dependent on cumulative IFX exposure. The efficacy of ADA for perianal fistula with CD is still not very clear because a dedicated controlled study has not yet been done. Castaño-Milla et al.8 reported retrospective data showing that ADA was effective for the treatment of perianal fistulas in CD patients naive to anti-TNF drugs. Our study examined the clinical efficacy of ADA versus IFX in the treatment of perianal fistulas in CD and the risk factors for fistula tract recurrence or aggravation were analyzed.

The retrospective nature of this study was a limiting factor. The treatment of the IFX group began 5 years earlier than that of the ADA group. Thus, the follow-up period was longer in the IFX group. We compared the efficacy of ADA and IFX and found that there were no differences in gender, disease duration, age of CD onset, intestinal location, fistula classification, seton placement, IOIBD score, CRP, and frequency of injection between the two groups.

The rate of nonrecurrence or aggravation of fistula was 62.5% in the ADA group and 83.9% in the IFX group, during a follow-up period of 24 months. We hypothesized that ADA was less effective than IFX for anal fistula in CD but found that there was no significant statistical difference between the two forms of treatment. However, we found that the seton was an independent risk factor for recurrence or aggravation of the fistula tract. Although this risk factor did not correlate with fistula classification, we hypothesized that a risk factor may be the fistula classification itself, because we only used a seton in patients with a complex fistula. Patients with a complex fistula were likely to experience recurrence or aggravation. The results were consistent with the findings of a study by Tozer et al.15 We also found that the risk factors may be gender specific because no female patients in our study experienced recurrence or aggravation. However, further research is needed to support these findings. The rates of loss of response were 12.9% and 25.0% in the IFX and ADA groups, respectively. When a biologic shows a loss of response and the patient experiences a recurrence of fistula, we reinsert a seton and use another biologic.

In conclusion, our results suggest that ADA may be less effective than IFX in the treatment of perianal fistula in CD. Fistula classification may also be an important risk factor, as complex fistulas are more likely to show relapse or aggravation.

NOTES

Financial support: None.

Conflict of interest: None.

REFERENCES

1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424–1429.PMID: 17904915.Article PubMed
2. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology 2013;145:158–165.e2.PMID: 23583432.Article PubMed
3. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 2013;28:1148–1153.PMID: 23432198.Article PubMed
4. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000;43(10 Suppl): S85–S93.PMID: 11052483.Article PubMed
5. Penner A, Crohn BB. Perianal fistulae as a complication of regional ileitis. Ann Surg 1938;108:867–873.PMID: 17857277.Article PubMed PMC
6. Marzo M, Felice C, Pugliese D, et al. Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol 2015;21:1394–1403.PMID: 25663759.Article PubMed PMC
7. Hukkinen M, Pakarinen MP, Piekkala M, Koivusalo A, Rintala R, Kolho KL. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease. J Crohns Colitis 2014;8:756–762.PMID: 24447625.Article PubMed PDF
8. Castaño-Milla C, Chaparro M, Saro C, et al. Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015;49:34–40.PMID: 25485513.Article PubMed
9. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci 2013;9:765–779.PMID: 24273556.Article PubMed PMC
10. Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology 2003;125:1544–1546.PMID: 14598275.Article PubMed
11. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol 2013;48:31–72.PMID: 23090001.Article PubMed
12. Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn's disease. Colorectal Dis 2013;15:210–216.PMID: 22672653.Article PubMed
13. Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure. J Crohns Colitis 2010;4:654–660.PMID: 21122576.Article PubMed PDF
14. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006;23:1127–1136.PMID: 16611273.Article PubMed
15. Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflamm Bowel Dis 2012;18:1825–1834.PMID: 22223472.Article PubMed

Fig. 1

Cumulative rate of nonrecurrence or aggravation of fistula. IFX, infliximab; ADA, adalimumab.

Table 1

Patient Characteristics (n=47)

Characteristic	IFX (n=31)	ADA (n=16)	P-value
Sex (male/female)	27/4	14/2	0.670^a
Age of CD onset (yr)	29.2±8.9	32.4±9.7	0.710^b
Lesion site (large intestine and small intestine/small intestine/large intestine)	26/1/4	14/2/0	0.170^a
Disease duration (yr)	7.2±6.8	8.9±6.5	0.520^b
Fistula classification (simple/complex)	17/14	9/7	0.830^a
Seton placement (have/none)	20/10	11/5	0.850^a
Antibiotics (+/–)	29/2	14/2	0.870^a
5-ASA (+/−)	30/1	14/2	0.540^a
IM (+/–)	5/26	4/12	0.730^a
IOIBD score	3.1±1.6	2.3±0.9	0.170^b
CRP	4.2±3.5	2.1±2.5	0.070^b
Frequency	16.6±10.9	55.1±19.2	-
Follow-up period (mo)	68.1±11.7	36.1±3.9	0.008^b

Values are presented as mean±SD.

^aChi-square test.

^bStudent t-test.

IFX, infliximab; ADA, adalimumab; 5-ASA, 5-aminosalicylic acid; IM, immunomodulator; IOIBD, International Organization for the Study of Inflammatory Bowel Disease.

Table 2

Univariate Analysis of the Risk Factors for Recurrence or Aggravation

Risk factor	Nonrecurrence or aggravation	Recurrence or aggravation	P-value
Sex (male/female)	30/6	11/0	0.06^a
Age (≤16/17–39/≥40 yr)	4/27/5	0/10/1	0.28^a
Lesion site (large intestine and small intestine/small intestine/large intestine)	30/3/3	11/0/0	0.12^a
Disease duration (yr)	6.5±6.9	9.5±5.5	0.21^b
Fistula classification (simple/complex)	17/19	2/9	0.07^a
Seton placement (have/none)	21/15	10/1	0.02^a
IOIBD score	2.9±1.5	2.5±0.8	0.38^b
CRP	3.1±3.3	2.9±3.2	0.92^b
IFX/ADA	26/10	5/6	0.11^a
ED (+/−)	26/10	7/4	0.71^a
IM (+/−)	7/31	2/9	0.92^a
Follow-up period (mo)	59.0±17.0	50.0±18.8	0.27^b

Values are presented as number or mean±SD.

^aChi-square test.

^bStudent t-test.

IOIBD, International Organization for the Study of Inflammatory Bowel Disease; IFX, infliximab; ADA, adalimumab; ED, elemental diet; IM, immunomodulator.

Table 3

Multivariate Analysis of the Risk Factors for Recurrence or Aggravation

Risk factor	OR	95% CI	P-value
IFX or ADA	6.0	0.855–42.470	0.530
Fistula classification	2.9	0.365–24.493	0.290
Seton	17.2	1.463–202.232	0.007

Logistic regression.

IFX, infliximab; ADA, adalimumab.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Epidemiology and Treatment Patterns of Fistulizing Crohn’s Disease in a Large, Real-World Australasian Cohort
Jack McNamara, William Wilson, Joseph L. Pipicella, Simon Ghaly, Jakob Begun, Ian C. Lawrance, Richard Gearry, Jane M. Andrews, Susan J. Connor
Gastro Hep Advances.2025; 4(4): 100594. CrossRef
Management of Perianal Fistulizing Crohn’s Disease
Arshdeep Singh, Vandana Midha, Gursimran Singh Kochhar, Bo Shen, Ajit Sood
Inflammatory Bowel Diseases.2024; 30(9): 1579. CrossRef
Choosing Therapy for Moderate to Severe Crohn’s Disease
Malcolm Irani, Bincy Abraham
Journal of the Canadian Association of Gastroenterology.2024; 7(1): 1. CrossRef
The use of core descriptors from the ENiGMA code study in recent literature: a systematic review
Saher‐Zahra Khan, Andrea Arline, Kate M. Williams, Matthew J. Lee, Emily Steinhagen, Sharon L. Stein
Colorectal Disease.2024; 26(3): 428. CrossRef
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review
Mohammad Shehab, Davide De Marco, Peter L. Lakatos, Talat Bessissow
Expert Opinion on Biological Therapy.2024; 24(8): 733. CrossRef
Infliximab and Adalimumab in the Treatment of Fistulizing Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC4) Study
John David Chetwood, Sudarshan Paramsothy, Rupert W. Leong
American Journal of Gastroenterology.2024;[Epub] CrossRef
Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihi
Journal of Gastroenterology.2023; 58(4): 313. CrossRef
Perianal fistulas in Crohn's disease (review)
I. S. Anosov, B. A. Nanaeva, A. V. Vardanyan, M. A. Zakharov
Koloproktologia.2023; 22(1): 128. CrossRef
Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Digestive Diseases and Sciences.2023; 68(10): 3994. CrossRef
Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
Gustavo Drügg Hahn, Petra Anna Golovics, Panu Wetwittayakhlang, Alex Al Khoury, Talat Bessissow, Peter Laszlo Lakatos
Biomedicines.2022; 10(4): 749. CrossRef
The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos
Journal of Clinical Medicine.2022; 11(11): 3045. CrossRef
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
Hua-Hua Yang, Yi Huang, Xu-Chun Zhou, Ruo-Nan Wang
World Journal of Clinical Cases.2022; 10(18): 6091. CrossRef
An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases
Tao Luo, Yile Wang, Hailin Tang, Fei Zhou, Ying Chen, Bing Pei, Jinke Wang
Journal of Inflammation Research.2022; Volume 15: 3447. CrossRef
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92. CrossRef
Predictors of reoperation for perianal fistula in Crohn's disease
Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung
Journal of Digestive Diseases.2021; 22(6): 334. CrossRef
Managing Complex Perianal Fistulizing Disease
Karina E. Pedersen, Amy L. Lightner
Journal of Laparoendoscopic & Advanced Surgical Techniques.2021; 31(8): 890. CrossRef
Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn’s disease treated with antitumor necrosis factor-alpha agents based on Parks’ classification
Nahla Azzam, Othman Alharbi, Majid Almadi, Abdulrahman Aljebreen, Turki AlAmeel, Mohammed Alabbas, Salman Bahammam, Ahmed Bashmail, Yasser Alomar, Mahmoud Mosli
European Journal of Gastroenterology & Hepatology.2020; 32(2): 187. CrossRef
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
The Korean Journal of Gastroenterology.2020; 75(1): 29. CrossRef
Characteristics of biological therapy in pediatric patients with Crohn’s disease
Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres
Expert Opinion on Biological Therapy.2019; 19(3): 181. CrossRef
Endorectal Advancement Flaps for Perianal Fistulae in Crohn’s Disease: Careful Patient Selection Leads to Optimal Outcomes
Michelle T. Roper, Stephen M. Trinidad, Sonia L. Ramamoorthy, Lisa A. Parry, Nicole E. Lopez, Sergey Khaitov, Randolph Steinhagen, Samuel G. Eisenstein
Journal of Gastrointestinal Surgery.2019; 23(11): 2277. CrossRef
Maneuvering Clinical Pathways for Crohn’s Disease
Thomas X. Lu, Russell D. Cohen
Current Gastroenterology Reports.2019;[Epub] CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Journal of Gastroenterology and Hepatology.2019; 34(8): 1296. CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Intestinal Research.2019; 17(3): 285. CrossRef
Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics
Toshihiro Inokuchi, Sakuma Takahashi, Sakiko Hiraoka, Tatsuya Toyokawa, Shinjiro Takagi, Koji Takemoto, Jiro Miyaike, Tsuyoshi Fujimoto, Reiji Higashi, Yuki Morito, Toru Nawa, Seiyuu Suzuki, Mamoru Nishimura, Masafumi Inoue, Jun Kato, Hiroyuki Okada
Journal of Gastroenterology and Hepatology.2019; 34(8): 1329. CrossRef
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
Jong Pil Im
Intestinal Research.2017; 15(2): 147. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease

Intest Res. 2017;15(2):182-186. Published online April 27, 2017

DOI: https://doi.org/10.5217/ir.2017.15.2.182

XML Download

Figure

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease

Fig. 1 Cumulative rate of nonrecurrence or aggravation of fistula. IFX, infliximab; ADA, adalimumab.

Fig. 1

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease

Table 1

Patient Characteristics (n=47)

Characteristic	IFX (n=31)	ADA (n=16)	P-value
Sex (male/female)	27/4	14/2	0.670^a
Age of CD onset (yr)	29.2±8.9	32.4±9.7	0.710^b
Lesion site (large intestine and small intestine/small intestine/large intestine)	26/1/4	14/2/0	0.170^a
Disease duration (yr)	7.2±6.8	8.9±6.5	0.520^b
Fistula classification (simple/complex)	17/14	9/7	0.830^a
Seton placement (have/none)	20/10	11/5	0.850^a
Antibiotics (+/–)	29/2	14/2	0.870^a
5-ASA (+/−)	30/1	14/2	0.540^a
IM (+/–)	5/26	4/12	0.730^a
IOIBD score	3.1±1.6	2.3±0.9	0.170^b
CRP	4.2±3.5	2.1±2.5	0.070^b
Frequency	16.6±10.9	55.1±19.2	-
Follow-up period (mo)	68.1±11.7	36.1±3.9	0.008^b

Values are presented as mean±SD.

^aChi-square test.

^bStudent t-test.

IFX, infliximab; ADA, adalimumab; 5-ASA, 5-aminosalicylic acid; IM, immunomodulator; IOIBD, International Organization for the Study of Inflammatory Bowel Disease.

Table 2

Univariate Analysis of the Risk Factors for Recurrence or Aggravation

Risk factor	Nonrecurrence or aggravation	Recurrence or aggravation	P-value
Sex (male/female)	30/6	11/0	0.06^a
Age (≤16/17–39/≥40 yr)	4/27/5	0/10/1	0.28^a
Lesion site (large intestine and small intestine/small intestine/large intestine)	30/3/3	11/0/0	0.12^a
Disease duration (yr)	6.5±6.9	9.5±5.5	0.21^b
Fistula classification (simple/complex)	17/19	2/9	0.07^a
Seton placement (have/none)	21/15	10/1	0.02^a
IOIBD score	2.9±1.5	2.5±0.8	0.38^b
CRP	3.1±3.3	2.9±3.2	0.92^b
IFX/ADA	26/10	5/6	0.11^a
ED (+/−)	26/10	7/4	0.71^a
IM (+/−)	7/31	2/9	0.92^a
Follow-up period (mo)	59.0±17.0	50.0±18.8	0.27^b

Values are presented as number or mean±SD.

^aChi-square test.

^bStudent t-test.

IOIBD, International Organization for the Study of Inflammatory Bowel Disease; IFX, infliximab; ADA, adalimumab; ED, elemental diet; IM, immunomodulator.

Table 3

Multivariate Analysis of the Risk Factors for Recurrence or Aggravation

Risk factor	OR	95% CI	P-value
IFX or ADA	6.0	0.855–42.470	0.530
Fistula classification	2.9	0.365–24.493	0.290
Seton	17.2	1.463–202.232	0.007

Logistic regression.

IFX, infliximab; ADA, adalimumab.

Table 1 Patient Characteristics (n=47)

Values are presented as mean±SD.

^aChi-square test.

^bStudent t-test.

IFX, infliximab; ADA, adalimumab; 5-ASA, 5-aminosalicylic acid; IM, immunomodulator; IOIBD, International Organization for the Study of Inflammatory Bowel Disease.

Table 2 Univariate Analysis of the Risk Factors for Recurrence or Aggravation

Values are presented as number or mean±SD.

^aChi-square test.

^bStudent t-test.

IOIBD, International Organization for the Study of Inflammatory Bowel Disease; IFX, infliximab; ADA, adalimumab; ED, elemental diet; IM, immunomodulator.

Table 3 Multivariate Analysis of the Risk Factors for Recurrence or Aggravation